EXAS Price Prediction Next Week
Analysis and Insights
To predict the stock price of Exact Sciences (EXAS) for the next trading week, we analyze both news sentiment and technical indicators.
News Sentiment Analysis:
- Analyst Ratings: Piper Sandler lowered the price target for EXAS from $75 to $70 while maintaining an Overweight rating. Scotiabank raised the price target to $73, while BTIG lowered it to $65, indicating mixed analyst sentiment.
- Ark Invest's Action: Ark Invest sold 80,270 shares of EXAS, reflecting a notable reduction in their position.
- Investor Conferences: EXAS is scheduled to participate in March investor conferences, which could positively impact sentiment.
Technical Analysis:
- RSI: The RSI for EXAS is 35.42, indicating oversold conditions.
- MACD: The MACD is negative (-1.86), signaling bearish momentum.
- SMA: The stock is trading below its 20, 50, and 200-day moving averages.
- Fibonacci Levels: Resistance levels at $51.01 and $52.51, with support at $46.14 and $44.64.
Price Prediction:
Based on the oversold RSI and potential positive news from investor conferences, EXAS may experience a short-term rebound. The price target for next week is $48.50.
Recommendation:
Buy EXAS at the current price of $46.51, anticipating a rebound toward the $48.50 level.
EXAS Similar Chart Price Prediction
The price of EXAS is predicted to go up -4.73%, based on the high correlation periods with YUMC. The similarity of these two price pattern on the periods is 97.88%.
EXAS
YUMC
Down: -4.73%Similarity: 97.88%
EXAS Revenue Forecast
EXAS EPS Forecast
EXAS FAQs
What is EXAS revenue forecast for next quarter？
What is EXAS eps forecast for next quarter？
EXAS VS S&P500
Cologuard's staying power is underappreciated. It could take years for liquid biopsy to steal share, and Cologuard's market share could soar past 10%.
Exact is positioned for growth regardless of how liquid biopsies play out, and the firm's liquid biopsy initiative is a good hedge in case Cologuard feels competitive pressure.
Exact has a robust pipeline of liquid biopsy offerings, including minimal residual disease (MRD), multicancer early detection (MCED), and CRC screening.
EXAS Analyst's Forecast
Gerard Cassidy
RBC Capital
Hold
2025-03-13
Price Target
$52
Upside
+20.82%
RBC Capital initiated coverage of Exact Sciences with a Sector Perform rating and $52 price target while launching coverage of the Liquid Biopsy space. Exact is the leader in colorectal cancer with its at-home test, Cologuard, the analyst noted. While it has had success displacing traditional screening methods for CRC, new competitive entrants are likely to dampen Exact's growth going forward and the stool-based testing method does not transfer over to other areas of cancer testing so the firm contends that it is unclear if the company will have success with its upcoming product launches.
David Westenberg
Piper Sandler
Buy
2025-02-26
Price Target
$75 → $70
Upside
+44.33%
Sung Ji Nam
Scotiabank
Buy
2025-02-24
Price Target
$70 → $73
Upside
+42.36%
